AlphaStocks
5.7
Consider Buy

LIGAND PHARMACEUTICALS INC (LGND)

Health Care / Biotechnology

S&P SmallCap 600

$199.82

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

#380out of 1127 in Health Care

Is LIGAND PHARMACEUTICALS INC a Good Investment in 2026?

LIGAND PHARMACEUTICALS INC (LGND) scores 5.7 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates LIGAND PHARMACEUTICALS INC as Attractive (5/9). However, the Graham model rates it Caution — Significantly above fair value. LIGAND PHARMACEUTICALS INC currently trades above its estimated fair value of $134, suggesting limited upside at current prices. LIGAND PHARMACEUTICALS INC ranks #380 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E32.6ROE12.7Market Cap4B

Estimated Fair Value

$133.5750% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 2.0 · Fast Grower

Greenblatt

Neutral

Bottom half (rank 59%)

Frequently Asked Questions

Is LIGAND PHARMACEUTICALS INC (LGND) a good investment?
Based on AlphaStocks' composite analysis, LIGAND PHARMACEUTICALS INC (LGND) scores 5.7 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading above estimated fair value — the market may be pricing in future growth.
What is LIGAND PHARMACEUTICALS INC's Piotroski F-Score?
LIGAND PHARMACEUTICALS INC's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is LGND overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $134, LGND appears overvalued. The stock currently trades 50% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does LGND compare to other Health Care stocks?
LIGAND PHARMACEUTICALS INC ranks #380 out of 1127 stocks in the Health Care sector, placing it in the top 34% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about LGND?
AlphaStocks evaluates LGND using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 5.7/10.

Similar Stocks

PARRFTIAZN

Compare LGND with

LGND vs PARRLGND vs FTILGND vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer